Name | Tefinostat |
Description | Tefinostat (CHR-2845) is a potent monocyte/macrophage-targeted histone deacetylase (HDAC) inhibitor that is cleaved to the active acid CHR-2847 by intracellular esterase human carboxylesterase-1 (hCE-1). Tefinostat exhibits antitumor activity and can be used in the study of leukemia and advanced hematologic malignancies. |
In vitro | Tefinostat (1-4 nM; AML cell lines) demonstrates efficacy in AML cell lines, including HL60 (M2 FAB type), MV411 (M4, FLT3-ITD), OCIAML3 (M4 NPM1mut), and THP1 (M5), with EC50 values of 2.3 μM, 57 nM, 110 nM, and 560 nM, respectively. |
Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 90 mg/mL (181.59 mM), Sonication is recommended.
|
Keywords | Tefinostat | CHR2845 | CHR 2845 |
Inhibitors Related | Valproic acid sodium salt | Panobinostat | Theophylline monohydrate | Sodium 4-phenylbutyrate | Vorinostat | Acefylline | Valproic Acid | Curcumin | Parthenolide | 4-Phenylbutyric acid | Theophylline | Methyl L-histidinate dihydrochloride |
Related Compound Libraries | Histone Modification Compound Library | DNA Damage & Repair Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |